Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ABVC

ABVC BioPharma Inc

Apr 18 • 04:00PM ET

1.05

Dollar change +0.03
Percentage change 2.94	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.45	Insider Own	17.84%	Shs Outstand	10.56M	Perf Week	-8.70%
Market Cap	11.09M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.68M	Perf Month	-6.25%
Income	-10.52M	PEG	-	EPS next Q	-	Inst Own	1.05%	Short Float	15.17%	Perf Quarter	-14.63%
Sales	0.15M	P/S	73.92	EPS this Y	-	Inst Trans	-81.20%	Short Ratio	1.80	Perf Half Y	20.11%
Book/sh	1.11	P/B	0.94	EPS next Y	-	ROA	-80.41%	Short Interest	1.32M	Perf Year	-84.12%
Cash/sh	0.08	P/C	13.86	EPS next 5Y	-	ROE	-158.22%	52W Range	0.67 - 9.60	Perf YTD	-9.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.78%	ROI	-113.72%	52W High	-89.06%	Beta	0.81
Dividend TTM	-	Quick Ratio	0.28	Sales past 5Y	2003.75%	Gross Margin	-112.28%	52W Low	55.81%	ATR (14)	0.10
Dividend Ex-Date	Sep 16, 2013	Current Ratio	0.28	EPS Y/Y TTM	53.37%	Oper. Margin	-5390.35%	RSI (14)	38.86	Volatility	10.65% 9.44%
Employees	19	Debt/Eq	0.28	Sales Y/Y TTM	-84.28%	Profit Margin	-6898.68%	Recom	3.00	Target Price	20.20
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	73.75%	Payout	-	Rel Volume	0.63	Prev Close	1.02
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-99.63%	Earnings	Nov 15 BMO	Avg Volume	733.34K	Price	1.05
SMA20	-10.95%	SMA50	-13.77%	SMA200	-34.62%	Trades		Volume	459,039	Change	2.94%

Today 09:25AM	AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share (GlobeNewswire)
Apr-17-24 09:00AM	ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M (GlobeNewswire) -8.93%
Apr-10-24 08:30AM	ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M (GlobeNewswire)
Mar-26-24 08:30AM	ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M (GlobeNewswire) +21.90%
Mar-21-24 08:30AM	AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars (GlobeNewswire)
08:30AM	Loading…
Mar-19-24 08:30AM	ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine (GlobeNewswire)
Mar-14-24 09:30AM	ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update (GlobeNewswire)
Feb-27-24 08:30AM	ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars (GlobeNewswire)
Feb-15-24 08:30AM	ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues (GlobeNewswire)
Feb-12-24 08:30AM	ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Feb-08-24 09:17AM	ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share (GlobeNewswire) -7.14%
Jan-03-24 07:24AM	ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees (GlobeNewswire) +60.83%
Dec-07-23 08:30AM	ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study (GlobeNewswire) -7.41%
Dec-05-23 08:30AM	ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials (GlobeNewswire)
Nov-21-23 08:30AM	ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market (GlobeNewswire) +5.33%
10:05AM	Loading…
Nov-16-23 10:05AM	ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M (GlobeNewswire) +27.20%
Nov-15-23 09:00AM	ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results (GlobeNewswire) +11.61%
Oct-26-23 08:30AM	ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million (GlobeNewswire) +50.59%
Oct-17-23 08:30AM	ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study (GlobeNewswire) -7.00%
Oct-09-23 08:30AM	ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Aug-23-23 08:30AM	ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study (GlobeNewswire)
Aug-17-23 09:19AM	ABVC Executes Cooperation Agreement for Strategic Investments (GlobeNewswire) -7.22%
Aug-10-23 08:30AM	ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -8.82%
Aug-07-23 08:30AM	ABVC Corporate Update and CEO's Letter to Shareholders (GlobeNewswire) -5.47%
Aug-03-23 09:20AM	ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration (GlobeNewswire)
Aug-01-23 08:30AM	ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales (GlobeNewswire) +44.98%
Jul-31-23 09:30AM	ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering (GlobeNewswire) -7.43%
Jul-27-23 09:22AM	ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering (GlobeNewswire) -41.73%
Jul-26-23 08:30AM	ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments (GlobeNewswire) +40.00%
Jul-24-23 12:30PM	ABVC BioPharma Announces Reverse Stock Split (GlobeNewswire)
08:30AM	Loading…
Jul-06-23 08:30AM	The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency (GlobeNewswire) -6.49%
Jun-26-23 08:30AM	ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth (GlobeNewswire) +7.54%
Jun-20-23 08:30AM	ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production (GlobeNewswire) +7.90%
Jun-12-23 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF (GlobeNewswire)
Jun-06-23 08:30AM	ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization (GlobeNewswire)
May-22-23 08:30AM	ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia (GlobeNewswire) -5.42%
May-04-23 08:30AM	ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Apr-26-23 08:30AM	ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF (GlobeNewswire)
Apr-10-23 08:30AM	ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) (GlobeNewswire)
Apr-06-23 08:30AM	ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand (GlobeNewswire)
Mar-31-23 06:49PM	ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results (GlobeNewswire)
Mar-20-23 07:00AM	ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand (PR Newswire) +8.32%
Mar-14-23 07:00AM	ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare (PR Newswire) +11.21%
Feb-28-23 08:30AM	ABVC BioPharma Provides 2023 Pipeline Update (GlobeNewswire)
Feb-23-23 04:16PM	ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials (GlobeNewswire)
Feb-21-23 08:30AM	ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® (GlobeNewswire) +6.21%
Jan-19-23 08:30AM	ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference (GlobeNewswire)
Jan-18-23 08:25AM	ABVC: Several Potential Paths to Achieving Near-Term Milestones (Zacks Small Cap Research) -6.04%
Jan-05-23 08:30AM	FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer (GlobeNewswire) +72.58%
Dec-20-22 11:05AM	ABVC: Key Medical Venues Participating in Clinical Studies (Zacks Small Cap Research)
Nov-17-22 08:30AM	ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval (GlobeNewswire)
05:16AM	ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 06:20PM	ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results (GlobeNewswire)
Nov-07-22 08:30AM	ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) (GlobeNewswire)
Nov-02-22 08:30AM	Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharmas Medication for Treating Depression in Cancer Patients (GlobeNewswire)
Oct-05-22 08:30AM	ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia (GlobeNewswire)
Sep-23-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval (GlobeNewswire) +12.72%
Sep-16-22 09:36AM	ABVC: Moving Lead Assets Forward and Expanding Development Pipeline (Zacks Small Cap Research) -27.00%
Sep-13-22 08:30AM	ABVC Biopharma Announces Letter to Shareholders (GlobeNewswire)
Sep-09-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Site (GlobeNewswire)
Aug-22-22 08:30AM	ABVC Provides Oncology Pipeline Updates (GlobeNewswire)
Aug-18-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire) +19.62%
Aug-15-22 05:48PM	ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.76%
Aug-02-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire)
Jul-18-22 08:30AM	ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028 (GlobeNewswire)
Jul-13-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update (GlobeNewswire)
Jul-06-22 08:30AM	Zacks Places Share Value of ABVC BioPharma at $9.50 (GlobeNewswire)
Jun-30-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire)
Jun-21-22 08:30AM	ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation (GlobeNewswire)
Jun-16-22 08:30AM	ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC (GlobeNewswire)
Jun-10-22 08:30AM	ABVC BioPharma Announces Termination of Two Contracts (GlobeNewswire) -47.37%
Jun-07-22 01:10PM	ABVC: Enrollment in ABV-1505 Part 2 ADHD Clinical Study Continues; First Patient Begins Treatment (Zacks Small Cap Research)
Jun-01-22 08:30AM	ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study (GlobeNewswire)
May-25-22 08:30AM	ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners (GlobeNewswire)
May-23-22 07:30AM	Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines (GlobeNewswire)
May-16-22 05:46PM	ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.78%
03:25PM	WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering (PR Newswire)
May-13-22 08:30AM	ABVC BioPharma Engages the FreeMind Group to Support Grant Funding (GlobeNewswire) +6.13%
May-12-22 09:00AM	WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering (PR Newswire) -13.47%
08:30AM	ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering (GlobeNewswire)
May-10-22 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated (GlobeNewswire) +8.24%
May-05-22 08:30AM	ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process (GlobeNewswire)
May-03-22 08:30AM	ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed (GlobeNewswire)
Apr-28-22 08:30AM	ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study (GlobeNewswire)
Apr-26-22 08:30AM	ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting (GlobeNewswire)
Mar-31-22 04:18PM	ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results (GlobeNewswire)
Mar-23-22 09:25AM	ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-08-22 06:15AM	ABVC: Lead Products Move Closer To Potential Approval; Important Clinical Studies Advancing (Zacks Small Cap Research)
Feb-02-22 08:00AM	ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study (GlobeNewswire)
Jan-05-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites (GlobeNewswire)
Dec-22-21 08:30AM	ABVC BioPharmas Vitreous Substitute Vitargus Presented at 14th APVRS Congress (GlobeNewswire)
Dec-15-21 08:30AM	ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award (GlobeNewswire) +8.85%
Dec-10-21 01:38PM	Why ABVC BioPharma Shares Are Trading Higher On Friday? (Benzinga) +5.14%
05:17AM	ABVC: Moving Forward on Several 2022 Goals to Advance Growth Strategy (Zacks Small Cap Research)
Dec-09-21 08:30AM	ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement (GlobeNewswire)
Nov-15-21 04:33PM	ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results (GlobeNewswire) +7.23%
Nov-11-21 09:00AM	ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M (GlobeNewswire)
Nov-03-21 11:18AM	10 Best Stocks For Day Trading (Insider Monkey) -7.42%
Nov-02-21 06:18AM	What Percentage Of ABVC BioPharma, Inc. (NASDAQ:ABVC) Shares Do Insiders Own? (Simply Wall St.) -26.20%
Nov-01-21 11:32AM	ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today (InvestorPlace) +137.40%

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVC

ABVC BioPharma Inc

Upgrade your FINVIZ experience